high product concentr top three us product account half profit
cadila high product concentr us glialda
levorphanol sentynl asacol hd account almost half
profit asacol may see gener competit
year competit expect lialda
gener levorphanol mn
annualis product patent protect attract
competit stay neutral due high concentr
cadila confirm base busi price eros qoq
impli qoq declin us led tamiflu
contribut higher expect like lupin
result result margin weak ebitda miss
cadila launch toprol-xl mn opportun
asacol hd start two boost margin
cadila expect authoris gener asacol
announc acquisit stake windla bn
mainli us-approv plant acquisit commecialis low-
valu approv cadila cut ep factor
weak result cut tp
estimate pot chg tp
 chang prev ep
note cadila healthcar diversifi indian pharmaceut compani focus develop
manufactur sell distribut product
click detail financi
figur weak us sale led quarter miss
tamiflu contribut base higher led miss
us sale declin mn qoq qoq vs expect
mn declin hit tamiflu higher expect
cadila mention call base busi eros ex lialda
tamiflu qoq impli contribut tamiflu
base much higher henc led larg miss
number suggest tamiflu mn
similar lupin result market underestim
contribut tamiflu lupin also report larg drop
weak margin led ebitda miss
gross margin weak bp declin qoq due impact
chines api price increas lower sale higher-margin
product us expens declin qoq due
freight cost save lower us sale also like lower
toprol-xl asacol hd launch
cadila alreadi launch toprol-xl mn annualis
opportun asacol hd start manag
confirm sale asacol larg stay similar margin
higher vs cadila expect authoris gener
come asacol hd
windla acquisit stake bn
windla manufactur facil us fda approv
recent inspect also receiv eir rational
acquisit use plant commercialis low-valu product
cadila us pipelin cadila got approv also
expect approv mani low-valu
opportun mn cadila plan commercialis
windla requir site transfer windla also
four ftf name tecfidera myrbetriq multaq latudaal
high gener competit
high product concentr cadila
cadila high product concentr us glialda
levorphanol sentynl product asacol hd account almost half
profit asacol may see gener competit year
competit expect lialda
gener levorphanol current mn annualis
product patent protect attract competit
figur ebitda miss weak us sale lower margin
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
price rate histori cadila healthcar cadi bo
signifi initi assumpt coverag
price rate histori lupin ltd lupn bo
signifi initi assumpt coverag
price rate histori teva pharmaceut teva
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european ra ting base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri regio nal benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stoc ks expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform wh ere less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap ne utral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sec tor
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requirem nt stock rate outperform neutral under-perform close correspond
